Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties

Fig. 6

Treatment with T1D-MSCs does not affect the frequency of Treg cells in spleens and PLNs of diabetic mice. Frequency of regulatory CD4+CD25+Foxp3+ T (Treg) cells was analyzed by flow cytometry in cell suspensions obtained from the a spleen and b PLN from T1D-MSC-treated, C-MSC-treated, and PBS-treated mice. Cells were stained for surface markers CD4 and CD25, and subsequently for the transcription factor Foxp3. Bars represent mean ± standard error of the mean. C-MSCs mesenchymal stromal cells from bone marrow of healthy individuals, PBS phosphate-buffered saline, PLN pancreatic draining lymph nodes, T1D-MSCs mesenchymal stromal cells from bone marrow of newly diagnosed T1D patients

Back to article page